Zacks Investment Research
19 May 2026, 15:30 UTC · 24w ago
Verdict
Headline takes no side. We score BAYRY +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA has accepted Bayer's new drug application (NDA) for asundexian, a once-daily oral Factor XIa inhibitor for preventing ischemic stroke.
More positive than 92% of claims this week
Phase III OCEANIC-STROKE study data showed asundexian significantly reduced ischemic stroke by 26% compared to placebo.
So whatPositive efficacy data from a large-scale trial (12,327 patients) increases the probability of final regulatory approval.
Continue reading
5 related stories
More positive than 85% of claims this week
The FDA granted asundexian Priority Review status, reducing the potential review period from 10 months to six months.
More positive than 75% of claims this week
The NDA for asundexian has also been accepted for review in Japan.
More positive than 47% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The FDA accepted the NDA for its drug asundexian and granted it Priority Review status.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
+38.1%
Price agrees with the score
$15.22 vs $11.02 close before publication (May 18) · not market-adjusted
BAYRY chart →
